Newborn affected by noxious substances transmitted via placenta or breast milk
Notes: Newborn affected by reactions and intoxications from maternal opiates and tranquilizers administered for procedures during pregnancy or labor and delivery ; Newborn affected by exposure in utero to tobacco smoke ; dysmorphism due to warfarin (Q86.2) ; fetal hydantoin syndrome (Q86.1) ; fetal alcohol syndrome (Q86.0) ; congenital malformations (Q00-Q99) ; encounter for observation of newborn for suspected diseases and conditions ruled out (Z05.-) ; neonatal jaundice from excessive hemolysis due to drugs or toxins transmitted from mother (P58.4) ; newborn in contact with and (suspected) exposures hazardous to health not transmitted via placenta or breast milk (Z77.-) ; newborn affected by other maternal medication (P04.1-) ; maternal anesthesia and analgesia in pregnancy, labor and delivery (P04.0) ; maternal use of drugs of addiction (P04.4-) ; newborn exposure to environmental tobacco smoke (P96.81) ; newborn affected by other maternal medication (P04.1-) ; newborn affected by maternal anesthesia and analgesia (P04.0) ; withdrawal symptoms from maternal use of drugs of addiction (P96.1) ; any current condition in newborn, if applicable ; withdrawal symptoms from maternal use of drugs of addiction, if applicable (P96.1)